Minerva Neurosciences (NERV) Total Liabilities (2013 - 2026)
Minerva Neurosciences posted quarterly Total Liabilities of $343.1 million for Q1 2026, up 453.83% year-on-year from $61.9 million in Q1 2025, and up 46.77% on a QoQ basis from $233.8 million in Q4 2025.
Minerva Neurosciences (NERV) has 14 years of Total Liabilities data on file, last reported at $343.1 million in Q1 2026.
- For the quarter ending Q1 2026, Total Liabilities rose 453.83% year-over-year to $343.1 million; the trailing twelve-month figure through Mar 2026 stood at $343.1 million (up 453.83% YoY), and the FY2025 full-year result was $233.8 million, up 272.0% from the prior year.
- Total Liabilities for Q1 2026 stood at $343.1 million, up from $233.8 million in the prior quarter.
- Across five years, Total Liabilities topped out at $343.1 million in Q1 2026 and bottomed at $61.9 million in Q1 2025.
- The 5-year median for Total Liabilities is $75.1 million (2022), against an average of $99.4 million.
- The widest annual swing landed in 2025, when Total Liabilities tumbled 31.12%; it then surged 453.83% in 2026.
- A 5-year view of Total Liabilities shows it stood at $75.1 million in 2022, then advanced by 13.64% to $85.4 million in 2023, then declined by 26.38% to $62.8 million in 2024, then soared by 272.0% to $233.8 million in 2025, then soared by 46.77% to $343.1 million in 2026.
- The last three Total Liabilities figures came in at $343.1 million (Q1 2026), $233.8 million (Q4 2025), and $62.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.74 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 731.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 177.22 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 19.51 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.12 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 10.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.45 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Minerva Neurosciences | 215.11 Mn | 215.11 Mn | - | 343.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 343.08 Mn |
| Dec 31, 2025 | 233.76 Mn |
| Sep 30, 2025 | 62.67 Mn |
| Jun 30, 2025 | 62.53 Mn |
| Mar 31, 2025 | 61.95 Mn |
| Dec 31, 2024 | 62.84 Mn |
| Sep 30, 2024 | 64.48 Mn |
| Jun 30, 2024 | 90.78 Mn |
| Mar 31, 2024 | 87.10 Mn |
| Dec 31, 2023 | 85.36 Mn |
| Sep 30, 2023 | 83.18 Mn |
| Jun 30, 2023 | 79.65 Mn |
| Mar 31, 2023 | 78.21 Mn |
| Dec 31, 2022 | 75.11 Mn |
| Sep 30, 2022 | 74.00 Mn |
| Jun 30, 2022 | 73.34 Mn |
| Mar 31, 2022 | 71.35 Mn |
| Dec 31, 2021 | 69.15 Mn |
| Sep 30, 2021 | 69.48 Mn |
| Jun 30, 2021 | 69.16 Mn |
| Mar 31, 2021 | 66.46 Mn |
| Dec 31, 2020 | 4.96 Mn |
| Sep 30, 2020 | 7.20 Mn |
| Jun 30, 2020 | 9.22 Mn |
| Mar 31, 2020 | 50.16 Mn |
| Dec 31, 2019 | 49.72 Mn |
| Sep 30, 2019 | 55.29 Mn |
| Jun 30, 2019 | 53.02 Mn |
| Mar 31, 2019 | 52.38 Mn |
| Dec 31, 2018 | 48.87 Mn |
| Sep 30, 2018 | 49.13 Mn |
| Jun 30, 2018 | 50.28 Mn |
| Mar 31, 2018 | 53.18 Mn |
| Dec 31, 2017 | 52.10 Mn |
| Sep 30, 2017 | 63.33 Mn |
| Jun 30, 2017 | 29.35 Mn |
| Mar 31, 2017 | 29.02 Mn |
| Dec 31, 2016 | 26.96 Mn |
| Sep 30, 2016 | 28.58 Mn |
| Jun 30, 2016 | 25.90 Mn |
| Mar 31, 2016 | 27.78 Mn |
| Dec 31, 2015 | 27.26 Mn |
| Sep 30, 2015 | 26.25 Mn |
| Jun 30, 2015 | 25.95 Mn |
| Mar 31, 2015 | 27.41 Mn |
| Dec 31, 2014 | 16.95 Mn |
| Sep 30, 2014 | 16.61 Mn |
| Jun 30, 2014 | 23.72 Mn |
| Dec 31, 2013 | 9.00 Mn |